Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopidogrel

Last updated: October 25, 2022
Sponsor: Chan Joon Kim
Overall Status: Active - Recruiting

Phase

N/A

Condition

Blood Clots

Hypercholesterolemia

Myocardial Ischemia

Treatment

N/A

Clinical Study ID

NCT05599152
CKD-HIRA-Data-Review
  • Ages > 18
  • All Genders

Study Summary

Myocardial infarction is defined according to icd-10 using the data base of South korea National Health Insurance Corporation, where personal identification information has already been removed, and detailed results are derived for each drug category.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients who have a diagnosis code for acute myocardial infarction indicated in theNational Health Insurance data and data for drugs that have used ticagrelor/prasugrelfor 30-90 days when hospitalized for the relevant disease.
  • Patients who switched to clopidogrel after 30-90 days.
  • Patients with a diagnosis code for Venus myocardial infarction and a prescription codefor percutaneous cardiovascular intervention in the National Health Insurance data.
  • Adults 18 years of age or older

Exclusion

Exclusion Criteria:

  • A person who has data for requesting blood transfusion during the period ofhospitalization in the National Health Insurance data
  • Those who have data for oral anticoagulants (warfarin, Coumadin, apixaban, edoxaban,dabigatran, rivaroxaban) in the National Health Insurance data
  • Those who have a diagnosis code for malignant tumor in the National Health Insurancedata
  • Those who have end-stage renal failure code in the National Health Insurance data orthose who have data for hemo/peritoneal dialysis
  • A person who has a request for blood transfusion during the period of usingTicagrelor/prasugrel

Study Design

Total Participants: 3000
Study Start date:
May 21, 2020
Estimated Completion Date:
November 30, 2022

Study Description

The purpose of this study is to compare the prognosis of patients with clopidogrel after early discontinuation of ticagrelor/prasugrel with patients who maintained aspirin and ticagrelor/prasugrel as standard therapy in patients with acute myocardial infarction who underwent percutaneous coronary intervention.

Connect with a study center

  • The Catholic University of Korea, Uijeongbu ST. Mary's Hospital

    Uijeongbu, 11765
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.